BioStock: Ultimovacs shows positive three-year data in skin cancer

Norwegian biotech Ultimovacs has recently presented positive three-year data for patients with metastatic malignant melanoma treated with cancer vaccine UV1 in combination with anti-PD-1 checkpoint inhibitor pembrolizumab. The results show both promising overall survival and an effect on predictive biomarkers, which strengthens the company's belief in UV1 as a combination treatment with today's checkpoint inhibitors for solid tumours. BioStock contacted Espen Basmo Ellingsen, Director Medical Affairst Ultimovacs, to find out more.

Read interview with Espen Basmo Ellingsen at biostock.se:

Ultimovacs shows positive three-year data in skin cancer - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/